26
May
2017
Tag: drug pricing
8
May
2017
Bionest
A Look at Duchenne Muscular Dystrophy: Part 2 – About DMD, and Approaches to Treatment, Old and New
Duchenne Muscular Dystrophy (DMD) is a rare genetic disease characterized by progressive muscle degeneration and weakness. It is one of the most frequent genetic disorders, affecting approximately 1 of 3,600 (primarily) male children. The disease is caused by a mutation in the gene for dystrophin on the X chromosome that results in the absence of...
2
May
2017
Bionest
A Look at Duchenne Muscular Dystrophy: Part 1 – Marathon Pharmaceuticals, PTC Therapeutics, and Drug Pricing
In February of this year, Marathon Pharmaceuticals received approval for Emflaza (deflazacort) tablets and oral suspension for the treatment of patients over the age of five years with Duchenne muscular dystrophy (DMD), regardless of the particular genetic mutation associated with their condition. The drug — an older corticosteroid with no patent protection which has...
1
Feb
2017
Bionest
Communicating Value
— Robert J. Easton, Co-Chairman, Bionest Partners During the annual January gathering of the biopharma world in San Francisco this year, in-coming President Donald J. Trump put drug developers on notice and sent pharmaceutical and biotechnology stock prices plunging by accusing the industry of “getting away with murder” with respect to drug pricing. ...
28
Nov
2016
Bionest
No Matter What You Think of the U.S. Election Outcome…
By Alain J. Gilbert, Co-Chair, Bionest Partners The U.S. Presidential election is over. No matter how you personally feel about the outcome, the fact of Donald Trump’s election is likely to be positive for the healthcare industry and biopharma. The reason: the issue of new drug pricing is not going to be a top...
26
Jul
2016
Bionest
Not Quite What the Headlines Suggest: Some Comments on Drug Pricing Issues
We recently had the opportunity to participate in an industry roundtable discussion on pharmaceutical pricing, organized by the editors of Life Science Leader. The discussion included perspectives from members of the pharmaceutical and biotech industry, patient advocates (from FasterCures and the National MS Society) and payers (CVS Health), as well as input from a Harvard...
6
Jul
2016
Bionest
Collective Wisdom Around Oncology – Comments on ASCO 2016
The Bionest Oncology team spent a jam packed and exciting five days at ASCO 2016 earlier this month in Chicago. More than 30,000 oncology professionals gathered from all around the world to discuss the latest data and innovations in oncology, and it did not disappoint. The theme of ASCO this year was Collective Wisdom, which...
24
Feb
2016
Bionest
Orphan Drug Franchises Best Left to Mature Alone
Commercial success in the rare disease field depends on a highly patient-centric approach that connects effectively with rare disease patient communities at a senior management level and focuses on access and interactions with thought leaders and physicians, rather than on selling drug features and benefits. This is the topic of our latest contributed article for...
21
Jan
2016